SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN)

BALA CYNWYD – March 30, 2023 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”) (Nasdaq- DFFN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to merge with EIP Pharma Inc. (“EIP Pharma”). Under the terms of the agreement, immediately after the merger, the current equity and convertible debt holders of EIP Pharma are expected to own, in the aggregate, approximately 77.25% of the total number of outstanding shares of common stock of the combined company and the current stockholders of Diffusion are expected to own approximately 22.75%.

The investigation concerns whether the Diffusion Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of Diffusion shareholders in the combined company.

If you own shares of Diffusion stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.